EC8 Stock Chart & Stats
€42.60
€0.00(0.00%)
At close: 4:00 PM EDT
€42.60
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€27.60 - €45.80
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€1.19B
Enterprise Value€1.78B
Total Cash (Recent Filing)€37.33M
Total Debt (Recent Filing)€834.25M
Price to Earnings (P/E)24.0
Beta0.49
Next Earnings
Oct 28, 2026EPS Estimate
0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.85
Shares Outstanding29,951,248
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)1.22
Price to Sales (P/S)0.92
P/FCF Ratio8.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€40.37Price Target Upside-5.23% Downside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)4.04
Revenue Forecast (FY)€1.22B
Bulls Say, Bears Say
Bulls Say
Diversified Surgical Product GrowthGrowth across both Orthopedic Surgery and General Surgery indicates demand is not reliant on a single product or procedure category. Continued adoption of AirSeal, Buffalo Filter, and BioBrace can support a broader, more resilient revenue base over the next several quarters.
Regulatory Support For Smoke EvacuationExpansion of surgical smoke evacuation requirements creates a structural demand tailwind for CONMED’s Buffalo Filter products. Wider regulation can encourage hospital adoption, enlarge the addressable market, and make this product category a durable contributor beyond short-term procedure fluctuations.
Positive Cash GenerationPositive operating and free cash flow demonstrate that CONMED’s medical-device operations are converting revenue into internally generated funding. This supports ongoing investment in products and operations while providing resources for debt service and other capital-allocation needs.
Bears Say
Compressed ProfitabilityThe sharp decline in net margin shows that recent revenue growth is producing less earnings than it did previously. Persistent cost, mix, or other operating pressures could limit reinvestment capacity and reduce the earnings benefit of continued sales expansion.
Meaningful Leverage And Interest BurdenDebt remains substantial relative to available cash and the company’s earnings base, even after refinancing simplified the capital structure. Higher leverage and increased interest costs reduce financial flexibility and could constrain acquisitions, product investment, or resilience if profitability stays compressed.
Moderate Debt Cash-Flow CoverageAlthough cash generation is positive, its scale relative to debt is not strong enough to support rapid deleveraging without sustained improvement. The lower full-year cash-flow outlook further reduces near-term repayment capacity and leaves greater dependence on continued operating execution.
Conmed News
EC8 FAQ
What was Conmed’s price range in the past 12 months?
Conmed lowest stock price was €27.60 and its highest was €45.80 in the past 12 months.
What is Conmed’s market cap?
Conmed’s market cap is €1.19B.
When is Conmed’s upcoming earnings report date?
Conmed’s upcoming earnings report date is Oct 28, 2026 which is in 15 days.
How were Conmed’s earnings last quarter?
Conmed released its earnings results on Jul 29, 2026. The company reported €1.231 earnings per share for the quarter, beating the consensus estimate of €0.99 by €0.241.
Is Conmed overvalued?
According to Wall Street analysts Conmed’s price is currently Overvalued.
Does Conmed pay dividends?
Conmed does not currently pay dividends.
What is Conmed’s EPS estimate?
Conmed’s EPS estimate is 0.89.
How many shares outstanding does Conmed have?
Conmed has 29,951,248 shares outstanding.
What happened to Conmed’s price movement after its last earnings report?
Conmed reported an EPS of €1.231 in its last earnings report, beating expectations of €0.99. Following the earnings report the stock price went up 7.447%.
Which hedge fund is a major shareholder of Conmed?
Currently, no hedge funds are holding shares in DE:EC8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Conmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€40.37 (-5.23% Downside)
€40.37 (-5.23% Downside)
Blogger Sentiment
Bullish
DE:EC8 Sentiment 60%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.18%
12-Months-Change
Fundamentals
Return on Equity
5.51%
Trailing 12-Months
Asset Growth
-1.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Conmed
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
EC8 Company Deck
EC8 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive operational and financial progress: organic revenue growth exceeded expectations (+6% organic), adjusted EPS rose 20% driven partly by a one-time tariff refund, gross margins and operating margins expanded, free cash flow in Q2 increased materially (+46% YoY), key growth products (Buffalo Filter, BioBrace, AirSeal) advanced with regulatory and clinical tailwinds, portfolio optimization and a meaningful refinancing were completed, and experienced leadership additions were made. Offsetting items included AirSeal growth below near-term expectations, flat U.S. orthopedics, higher expected interest expense and tax rate, a lowered top-end of revenue guidance, and a reduced full-year free cash flow target driven by working capital. Overall, highlights outweigh the lowlights, but several non-recurring benefits and near-term headwinds temper the outlook.View all DE:EC8 earnings summariesEC8 Stock 12 Month Forecast
Average Price Target
€40.37
▼(-5.23% Downside)
Technical Analysis
Enovis
―
Integra Lifesciences
―
Smith & Nephew Snats
―
Stryker
―
Zimmer Biomet Holdings
―